Whole Genome Sequencing (Veritas)

Whole Genome Sequencing (Veritas)

Whole genome sequencing reads all three billion base pairs of an individual's DNA — not the fraction consumer tests sample — to reveal hereditary disease risk, medication response, and carrier status. Offered through Quantitative Health using Veritas Intercontinental, the whole-genome platform co-founded with Harvard geneticist George Church, and interpreted by Dr. Paul Kilgore, MD, MPH, FACP.

A single saliva sample analyzes 576+ genes across 650+ actionable conditions, profiles how the individual metabolizes 250+ medications (pharmacogenomics), and screens 225+ carrier conditions — to ACMG clinical standards, with pre- and post-test genetic counseling included by Veritas's physician geneticists.

Dr. Kilgore's role is integration, not duplication: in an optional session, he places the genomic findings in the context of the individual's bloodwork, epigenetics, and wearable data — building one clinical strategy across all layers, and adding to the genetic counseling Veritas already provides.

For benefits and HR leaders, whole genome sequencing is a premium, preventive-medicine benefit — a one-time, lifetime genomic foundation that supports earlier screening and safer prescribing. Available individually or through corporate agreements at negotiated terms.